Skip to main content

Kathryn Dahir Archives

Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva

Sep. 28, 2023—A Vanderbilt clinical trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ossificans progressiva.

Read more


Diagnostic biomarker for bone disorder

Sep. 27, 2022—A urine chemical performs better as a diagnostic biomarker for the soft bone disease hypophosphatasia than other laboratory measures, Vanderbilt researchers have demonstrated.

Read more


National XLH Day

Aug. 11, 2022—Vanderbilt recently hosted the National XLH (X-linked hypophosphatemia) Day, and more than 200 patients and families attended.

Read more


Faculty awards honor teaching, clinical, research excellence

May. 5, 2022—The 2022 Vanderbilt University School of Medicine Academic Enterprise Awards for Excellence in Teaching, Extraordinary Performance of Clinical Service, and Outstanding Contributions to Research were presented April 29 during the annual spring faculty meeting.

Read more


Dahir receives grant to support study of rare metabolic disorder

Aug. 17, 2017—Kathryn Dahir, M.D., associate professor of Medicine in the Division of Diabetes, Endocrinology and Metabolism, recently received the Maher Family Grant from Soft Bones Inc., an organization dedicated to providing information, education and support to those affected by hypophosphatasia (HPP).

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more